Business Context and Reporting Period
Company: Trisalus Life Sciences, Inc. (TLSI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: Trisalus is an oncology-focused medical technology company developing the Pressure Enabled Drug Delivery (PEDD) system (TriNav) and the investigational immunotherapeutic nelitolimod. The company operates as a single reporting segment.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6M 2025 | 6M 2024 |
|---|---|---|---|---|
| Revenue | $11,213 | $7,364 | $20,380 | $13,821 |
| Gross Profit | $9,411 | $6,452 | $17,083 | $11,938 |
| Gross Margin | 83.9% | 87.6% | 83.8% | 86.4% |
| Net Loss (Common Stockholders) | $(9,002) | $(5,133) | $(20,089) | $(19,140) |
| Cash and Cash Equivalents | $26,490 | N/A | $26,490 | N/A |
| Long-Term Debt (Net) | $32,274 | N/A | $32,274 | N/A |
| Accumulated Deficit | $(298,212) | N/A | $(298,212) | N/A |
Note: Q2 2024 comparative balance sheet data is not explicitly provided in the text for direct comparison, though income statement data is available.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 52.3% in Q2 2025 and 47.5% for the six months ended June 30, 2025, compared to the prior year periods. This was driven by a 52.5% increase in TriNav units sold and a price increase effective March 1, 2025.
- Gross Margin Compression: Gross margin decreased to 83.9% in Q2 2025 from 87.6% in Q2 2024. Management attributes this to lower manufacturing efficiency associated with newly launched products (TriNav LV and TriNav FLX) and a planned production shutdown.
- Operating Expenses:
- R&D: Decreased 15.9% in Q2 2025 due to reduced clinical trial expenses for nelitolimod.
- Sales & Marketing: Increased 19.3% in Q2 2025 due to headcount expansion and consultant utilization.
- G&A: Increased 43.0% in Q2 2025, primarily due to timing of professional services, filing, and audit expenses.
- Non-Cash Volatility: The change in fair value of the contingent earnout liability shifted from a $13.7 million gain in Q2 2024 to a $0.7 million gain in Q2 2025, driven by fluctuations in the company's stock price.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. Existing cash ($26.5 million) is deemed insufficient to fund projected liquidity requirements without additional financing.
- Recent Financing:
- Private Placement: Closed May 2, 2025, raising approximately $22.0 million gross proceeds from the sale of 5.5 million shares at $4.00/share.
- Debt Draw: Drew the $10.0 million First Delayed Draw Term Loan from OrbiMed on February 18, 2025, after meeting revenue targets.
- Preferred Stock Conversion: An offer to exchange Series A Convertible Preferred Stock for common stock expired July 23, 2025, with 98.8% tendered. All shares were converted by July 31, 2025, issuing 11.8 million common shares.
- Internal Control Weaknesses: The company identified material weaknesses in internal controls over financial reporting, including insufficient trained resources, inadequate controls over patent costs, R&D accruals, and complex financial instruments (SEPA, Warrants, OrbiMed debt).
- Regulatory Milestones: TriNav received a second permanent HCPCS code (C8004) effective April 1, 2025, for mapping procedures. Phase I data for nelitolimod in LA-PDAC is expected in 2025.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $26.5 million cash balance against the "substantial doubt" disclosure and the timeline for potential additional capital raises.
- Debt Covenants: Review the OrbiMed Credit Agreement terms, specifically the "Product Revenue Base" thresholds required to avoid mandatory principal repayments starting in future quarters.
- Preferred Stock Dilution: Confirm the impact of the July 2025 conversion of Series A Preferred Stock on fully diluted share count and earnings per share.
- Internal Controls: Assess the progress of the remediation plan for material weaknesses in financial reporting, particularly regarding complex derivative valuations and accruals.
- Reimbursement Stability: Monitor the adoption and reimbursement rates of the new HCPCS codes (C9797 and C8004) to ensure revenue sustainability post-TPT expiration.